Print

AB Science (AB.PA): Final Results Of Phase 3 Mastocytosis Study Expected By End Of 2014  
11/12/2013 1:36:49 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PARIS, Nov. 12, 2013 (GLOBE NEWSWIRE) -- AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), following the press release from November 11th that announced the phase 3 study's success in the futility analysis, further specifies important points concerning availability of phase 3 data, number of patients treatable and sustainability of response generated by masitinib observed in phase 2.

Help employers find you! Check out all the jobs and post your resume.

//-->